Search Results 881-890 of 17134 for monoclonal antibody

1. A Study to Evaluate the Safety and Effectiveness of JBH492 in Patients with Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma - Mayo Clinic

   ... monoclonal antibody administration. Any prior history of treatment with maytansine (DM1 or DM4)-based ADC. Known intolerance to a maytansinoid. Patients ...

2. Publications - Madiha Fida, M.B.B.S. - Mayo Clinic

   ... monoclonal antibody escape mutation in a persistently infected, immunocompromised individual. Virus Evol. 2023; 9 (2):veac104 Epub 2022 Nov 05. View PubMed ...

3. Open-label Trial of Daratumumab in Treatment of PGNIMD and C3 GN - Mayo Clinic

   ... monoclonal immune deposits (PGNMID) and C3 glomerulopathy associated with monoclonal gammopathy (C3GN). This is an inflammatory disease in the kidney due to ...

4. A Study to Evaluate the Safety and Effectiveness of MOR202 in Anti-PLA2R Antibody-positive Membranous Nephropathy - Mayo Clinic

   The purpose of this study is to assess the safety and tolerability of MOR202 treatment in subjects with Antibody Positive Membranous Nephropathy (aMN).

5. Daratumumab in Primary Antiphospholipid Syndrome (DARE-APS) - Mayo Clinic

   Any prior treatment with CD38 targeting monoclonal antibodies, including daratumumab or isatuximab-irfc;; Administration of the Janssen COVID-19 vaccine ...

6. Pulmonary Medicine - Clinical trials

   This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...

7. Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients with Relapsed or Refractory ALL - Mayo Clinic

   Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic ...

8. A Study of the Safety and Effectiveness of HBI-8000 with Nivolumab to Treat Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer - Mayo Clinic

   Participation eligibility · History of Grade 3 or above hypersensitivity reactions to other monoclonal antibodies. · Subjects with a history of a cardiovascular ...

9. A Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy in Patients with Gastric or Gastroesophageal Cancer - Mayo Clinic

   Prior allogeneic stem cell transplantation or organ transplantation. 17. History of severe hypersensitivity reactions to other monoclonal antibodies or any

10. A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants - Mayo Clinic

    ... monoclonal antibody (mAb) and for which no other more appropriate treatment option exists; At least one bidimensionally measurable lesion; Agreement to remain ...